GW Pharmaceuticals plc (GWPH) Is At $138.55 Formed Wedge; Rhythm Pharmaceuticals (RYTM) Shorts Raised By 71.85%

GW Pharmaceuticals plc (GWPH) formed wedge up with $142.71 target or 3.00% above today’s $138.55 share price. GW Pharmaceuticals plc (GWPH) has $3.85 billion valuation. The stock increased 1.36% or $1.86 during the last trading session, reaching $138.55. About 363,863 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 31.90% since January 28, 2017 and is uptrending. It has outperformed by 15.20% the S&P500.

Rhythm Pharmaceuticals Incorporated (NASDAQ:RYTM) had an increase of 71.85% in short interest. RYTM’s SI was 252,100 shares in January as released by FINRA. Its up 71.85% from 146,700 shares previously. With 114,300 avg volume, 2 days are for Rhythm Pharmaceuticals Incorporated (NASDAQ:RYTM)’s short sellers to cover RYTM’s short positions. The stock increased 3.95% or $1.21 during the last trading session, reaching $31.87. About 45,567 shares traded. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) has 0.00% since January 28, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 13 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. GW Pharmaceuticals had 25 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Buy” rating given on Monday, September 26 by Cantor Fitzgerald. The rating was maintained by Bank of America with “Buy” on Tuesday, November 14. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Goldman Sachs on Thursday, December 14. The rating was initiated by Janney Capital on Monday, June 27 with “Sell”. As per Monday, November 30, the company rating was initiated by TH Capital. Evercore initiated it with “Buy” rating and $154.0 target in Wednesday, August 16 report. The rating was maintained by Leerink Swann on Monday, October 2 with “Outperform”. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Overweight” rating given on Thursday, August 13 by Morgan Stanley. Numis Securities upgraded the shares of GWPH in report on Friday, August 26 to “Hold” rating. The stock has “Buy” rating by Maxim Group on Monday, August 7.

Analysts await GW Pharmaceuticals plc (NASDAQ:GWPH) to report earnings on February, 6. They expect $-2.10 earnings per share, down 172.73% or $1.33 from last year’s $-0.77 per share. After $-2.18 actual earnings per share reported by GW Pharmaceuticals plc for the previous quarter, Wall Street now forecasts -3.67% EPS growth.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. The company has market cap of $869.54 million. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. It currently has negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.